natgillin/translations-raw huggingface dataset:
abdominal pain, gastroesophageal reflux disease, constipation, dry mouth, oesophagitis, toothache, gastritis#
bol u trbuhu, gastroezofagealna refluksna bolest, konstipacija, suhoća usta, ezofagitis, zubobolja, gastritis#
Abdominal pain, Haematochezia, Mouth ulcer
bolovi u abdomenu, hematohezija, ulkus u ustima
Abdominal pain, intestinal obstruction, ileus/subileus, diverticulitis, intestinal perforation
bol u abdomenu, opstrukcija crijeva, ileus/subileus, divertikulitis i perforacija crijeva
Abdominal pain, lower
bol u donjem dijelu abdomena
Abdominal pain, Mouth ulceration, Gastritis
bol u abdomenu, ulceracije u ustima, gastritis
abdominal pain, nausea and vomiting
bol u abdomenu,
abdominal pain, nausea and vomiting
mučnina i povraćanje
abdominal pain, nausea or vomiting rapid deep breathing, drowsiness (which may indicate pancreatitis, liver disturbance such as hepatitis, or lactic acidosis).
bol u trbuhu, mučnina ili povraćanje ubrzano duboko disanje, pospanost (koje može upućivati na pankreatitis, poremećaje jetre kao što su hepatitis i laktacidoza).
abdominal pain, nausea or vomiting rapid deep breathing, drowsiness (which may indicate pancreatitis, liver disturbance such as hepatitis, or lactic acidosis).
bol u trbuhu, mučnina ili povraćanje, ubrzano duboko disanje, pospanost (koje može upućivati na pankreatitis, poremećaje jetre kao što su hepatitis i laktacidoza).
abdominal pain, nausea, constipation, swollen abdomen (signs of gastrointestinal disorders)
bol u trbuhu, mučnina, zatvor, nadutost trbuha (znakovi poremećaja probavnog sustava)
Abdominal pain, nausea, dyspepsia, diarrhoea, vomiting
Bol u abdomenu, mučnina, dispepsija, dijareja, povraćanje
abdominal pain, nausea, vomiting
bol u trbuhu, mučnina, povraćanje
abdominal pain, nausea, vomiting of blood, black stools, constipation, swollen abdomen (signs of gastrointestinal disorders)
bol u trbuhu, mučnina, povraćanje krvi, crna stolica, zatvor, nadutost trbuha (znakovi poremećaja probavnog sustava)
Abdominal pain, nausea, vomiting, diarrhoea, swelling and bloating of the abdomen, signs of inflammation of the stomach lining (gastroenteritis viral)
Bol u trbuhu, mučnina, povraćanje, proljev, oticanje i nadutost trbuha, znakovi upale sluznice želuca (virusni gastroenteritis)
Abdominal pain, nausea, vomiting, indigestion, frequent and/or loose stools
Bol u trbuhu, mučnina, povraćanje, probavne tegobe, česte i/ili mekane stolice
Abdominal pain, vomiting, diarrhoea dyspepsia*, stomatitis
bol u abdomenu, povraćanje, proljev, dispepsija*, stomatitis
abdominal pain, vomiting, nausea, bloating, diarrhea, soft stools,
Abdominalna bol, povraćanje, mučnina, nadutost, proljev, mekane stolice
abdominal pain, vomiting, nausea, constipation,
mišićno-koštana bol,
abdominal pain, vomiting, nausea, constipation,
povraćanje, mučnina, konstipacija, proljev,
abdominal pain, vomiting, nausea, constipation, diarrhoea, indigestion, toothache
bol u trbuhu, povraćanje, mučnina, zatvor, proljev, probavne tegobe, zubobolja
abdominal pain, vomiting, nausea, constipation, dysgeusia
bol u abdomenu, povraćanje, mučnina, konstipacija, disgeuzija
Abdominal pain, Vomiting, Nausea, Gastro-oesophageal reflux
bol u abdomenu, povraćanje, mučnina, gastroezofagealni refluks
Abdominal pain.
Bol u trbuhu.
Abdominal pain.
bol u trbuhu;
abdominal pain/abdominal pain upper,
bol u abdomenu/ bol u gornjem dijelu abdomena
abdominal pain/discomfort
bol/nelagoda u trbuhu
abdominal pain/discomfort, nausea, vomiting, haemorrhoids, haematochezia, mucous stools, dyspepsia, flatulence, dry mouth
bol /nelagoda u abdomenu, mučnina, povraćanje, hemoroidi, hematohezija, sluzave stolice, dispepsija, flatulencija, suha usta
Abdominal pain/discomfort/distension, constipation, nausea, vomiting
bol /nelagoda/distenzija abdomena, konstipacija, mučnina, povraćanje
Abdominal pain1
Bol u abdomenu1
abdominal pain1, 3, vomiting1, 3, increased lipase1, abdominal discomfort1, dry mouth1, flatulence3, diarrhea3
bol u abdomenu1,3, povraćanje1,3, povišena lipaza1, nelagoda u abdomenu1, suha usta1, flatulencija3, proljev3
Abdominal pain1, umbilical hernia1, vomiting, nausea
Bol u trbuhu1, umbilikalna hernija1, povraćanje, mučnina
abdominal pain2 mucositis
konstipacija bol u abdomenu2 mukozitis
abdominal pain;
bol u trbuhu,
abdominal pain;
bol u trbuhu;
Abdominal pain; Constipation; Diarrhoea; Nausea
bol u abdomenu, konstipacija, proljev, mučnina
Abdominal pain; Diarrhoea; Dyspepsia; Constipation; Nausea
bol u trbuhu; proljev; dispepsija; konstipacija; mučnina
abdominal pain; dry mouth; indigestion, bloating; numbness of the mouth
bol u trbuhu, suha usta, probavne tegobe, nadimanje, utrnulost usta
abdominal pain; uncomfortable feeling in the stomach or belching after eating; constipation; full or bloated feeling in the stomach; diarrhoea; flatulence,
bol u trbuhu, nelagoda u želucu ili podrigivanje nakon jela, zatvor, osjećaj težine u trbuhu ili nadutost, proljev, vjetrovi,
Abdominal paina
bol u abdomenua
Abdominal paina, diarrhoea
bol u abdomenua, proljev
Abdominal painC, diarrhoea, dyspepsiaD, gastritisD, nauseaC, vomitingD
bol u abdomenu C, proljev, dispepsijaD, gastritisD, mučninaC, povraćanjeD
Abdominal paine
Bol u abdomenue
Abdominal painf
bol u abdomenuf
Abdominal pain†
bol u abdomenu
Abdominal palpation should be sufficient to detect abnormal increases in splenic volume.
Palpacija abdomena trebala bi biti dovoljna za otkrivanje abnormalnog povećanja volumena slezene.
abdominal pressure
pritisak u abdomenu
abdominal pressure
pritisak u trbuhu
abdominal swelling
oticanje trbuha
Abdominal swelling or bloating,
otečenost ili nadutost trbuha,
Abdominal tenderness*
oralna parestezija osjetljivost abdomena
Abdominal wall abscess.
apsces trbušne stijenke.
Abdominal/stomach discomfort
abdominalna/želučana nelagoda
ABILIFY 1 mg/ml oral solution
ABILIFY 1 mg/ml oralna otopina
ABILIFY 1 mg/ml oral solution aripiprazole
ABILIFY 1 mg/ml oralna otopina aripiprazol
ABILIFY 1 mg/ml oral solution is a clear, colourless to light yellow liquid supplied in bottles with polypropylene child-resistant closure containing 50 ml, 150 ml or 480 ml per bottle.
ABILIFY 1 mg/ml oralna otopina je bistra, bezbojna do svijetložuta tekućina u boci s polipropilenskim sigurnosnim zatvaračem za djecu koja sadrži 50 ml, 150 ml ili 480 ml po boci.
ABILIFY 10 mg orodispersible tablets are round and pink, marked with ‘"A" over "640"’ on one side and ‘10’ on the other.
ABILIFY 10 mg raspadljive tablete za usta su okrugle i ružičaste, s oznakom ‘"A" iznad "640"’ na jednoj strani i ‘10’ na drugoj.
ABILIFY 10 mg orodispersible tablets: Red iron oxide (E 172) ABILIFY 15 mg orodispersible tablets: Yellow iron oxide (E 172) ABILIFY 30 mg orodispersible tablets: Red iron oxide (E 172)
ABILIFY 10 mg raspadljive tablete za usta: crveni željezov oksid (E 172) ABILIFY 15 mg raspadljive tablete za usta: žuti željezov oksid (E 172) ABILIFY 30 mg raspadljive tablete za usta: crveni željezov oksid (E 172)
ABILIFY 10 mg tablets are rectangular and pink, marked with ‘A-008’ and ‘10’ on one side.
ABILIFY 10 mg tablete su pravokutne i ružičaste, s oznakama ‘A-008’ i ‘10’ na jednoj strani.
ABILIFY 15 mg orodispersible tablets are round and yellow, marked with ‘"A" over "641"’ on one side and ‘15’ on the other.
ABILIFY 15 mg raspadljive tablete za usta su okrugle i žute, s oznakom ‘"A" iznad "641"’ na jednoj strani i ‘15’ na drugoj.
ABILIFY 15 mg tablets are round and yellow, marked with ‘A-009’ and ‘15’ on one side.
ABILIFY 15 mg tablete su okrugle i žute, s oznakama ‘A-009’ i ‘15’ na jednoj strani.
ABILIFY 15 mg tablets: Yellow iron oxide (E 172) ABILIFY 30 mg tablets: Red iron oxide (E 172)
ABILIFY 15 mg tablete: žuti željezov oksid (E 172) ABILIFY 30 mg tablete: crveni željezov oksid (E 172)
ABILIFY 30 mg (n = 25)
ABILIFY 30 mg (n = 30)
ABILIFY 30 mg orodispersible tablets are round and pink, marked with ‘"A" over "643"’ on one side and ‘30’ on the other.
ABILIFY 30 mg raspadljive tablete za usta su okrugle i ružičaste, s oznakom ‘"A" iznad "643"’ na jednoj strani i ‘30’ na drugoj.
ABILIFY 30 mg tablets are round and pink, marked with ‘A-011’ and ‘30’ on one side.
ABILIFY 30 mg tablete su okrugle i ružičaste, s oznakama ‘A-011’ i ‘30’ na jednoj strani.
ABILIFY 5 mg tablets are rectangular and blue, marked with ‘A-007’ and ‘5’ on one side.
ABILIFY 5 mg tablete su pravokutne i plave, s oznakama ‘A-007’ i ‘5’ na jednoj strani.
ABILIFY 5 mg tablets: Indigo carmine aluminium lake (E 132) ABILIFY 10 mg tablets: Red iron oxide (E 172)
ABILIFY 5 mg tablete: boja “indigo carmine aluminium lake” (E 132) ABILIFY 10 mg tablete: crveni željezov oksid (E 172)
ABILIFY 7.5 mg/ml solution for injection
ABILIFY 7,5 mg/ml otopina za injekciju
ABILIFY 7.5 mg/ml solution for injection aripiprazole
ABILIFY 7,5 mg/ml otopina za injekciju aripiprazol
Abilify also had a similar effect to haloperidol and to lithium over three weeks.
Abilify je također imao sličan učinak na haloperidol i litij tijekom tri tjedna.
Abilify is a medicine that contains the active substance aripiprazole.
Abilify je lijek koji sadrži djelatnu tvar aripiprazol.
Abilify is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over.
Abilify se također koristio do 12 tjedana za liječenje umjerenih do teških maničnih epizoda u bolesnika u dobi od 13 pa naviše.
ABILIFY is effective in a dose range of 10 to 30 mg/day (i.e.
ABILIFY je učinkovit u rasponu doza od 10 do 30 mg/dan (tj.
ABILIFY is effective in a dose range of 10 to 30 mg/day.
ABILIFY je učinkovit u rasponu doza od 10 do 30 mg/dan.
ABILIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).
ABILIFY je indiciran za liječenje umjerenih do teških maničnih epizoda u bipolarnom poremećaju tipa I te za prevenciju nove manične epizode u odraslih osoba s pretežno maničnim epizodama u kojih su prethodne manične epizode odgovorile na liječenje aripiprazolom (vidjeti dio 5.1).
ABILIFY is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).
ABILIFY je indiciran za liječenje umjerenih do teških maničnih epizoda u bipolarnom poremećaju tipa I u adolescenata u dobi od 13 godina i starijih tijekom najdulje 12 tjedana (vidjeti dio 5.1).
Abilify is used in adults to treat moderate to severe manic episodes and to prevent new manic episodes in adults who have responded to the medicine in the past.
Abilify se koristi u odraslih za liječenje umjerenih do teških maničnih epizoda i za sprječavanje novih maničnih epizoda u odraslih koji su reagirali na lijek u prošlosti.
Abilify is used in patients aged 15 years or over; bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood.
Abilify se koristi u bolesnika u dobi od 15 godina i više; bipolarni poremećaj tipa I, mentalna bolest kod koje bolesnici imaju manične epizode (razdoblja nenormalno dobrog raspoloženja) koje se izmjenjuju s normalnim razdobljima.
Abilify is used in patients with the following mental illnesses:
Abilify se koristi u bolesnika sa sljedećim mentalnim bolestima:
Abilify Maintena 300 mg injection aripiprazole
Abilify Maintena 300 mg injekcija aripiprazole
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe
Abilify Maintena 300 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Abilify Maintena 400 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Abilify Maintena 300 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem u napunjenoj štrcaljki
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Chemical and physical in-use stability has been demonstrated for 4 hours at 25°C. From a microbiological point of view, unless the method of opening/ reconstitution precludes the risk of microbial contamination, the product should be used immediately.
Abilify Maintena 300 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Abilify Maintena 400 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Pokazalo se da je lijek u primjeni kemijski i fizikalno stabilan 4 sata na temperaturi od 25 °C. S mikrobiološkog gledišta, lijek treba primijeniti odmah osim ako način otvaranja/rekonstitucije ne uklanja rizik od mikrobiološke kontaminacije.
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Powder and solvent for prolonged-release suspension for injection
Abilify Maintena 300 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Abilify Maintena 400 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection EU/1/13/882/001
Abilify Maintena 300 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem EU/1/13/882/001
Abilify Maintena 300 mg powder for prolonged-release injection aripiprazole
Abilify Maintena 300 mg prašak za injekciju s produljenim oslobađanjem aripiprazole i.m.
Abilify Maintena 400 mg injection aripiprazole
Abilify Maintena 400 mg injekcija aripiprazole
Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Each vial contains 400 mg aripiprazole.
Abilify Maintena 400 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Jedna bočica sadrži 400 mg aripiprazola.
Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection EU/1/13/882/002
Abilify Maintena 400 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem
Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe aripiprazole
Abilify Maintena 400 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem u napunjenoj štrcaljki. aripiprazol
Abilify Maintena 400 mg powder for prolonged-release injection aripiprazole
Abilify Maintena 400 mg prašak za injekciju s produljenim oslobađanjem aripiprazole i.m.
Abilify Maintena package leaflet and instructions for healthcare professionals.
Abilify Maintena uputa o lijeku i upute za zdravstvene djelatnike
Abilify Maintena should not be used to manage acutely agitated or severely psychotic states when immediate symptom control is warranted.
Abilify Maintena se ne smije koristiti za liječenje stanja akutne agitacije ili teških psihotičnih stanja kad je potrebna trenutna kontrola simptoma.
ABILIFY oral solution contains fructose, sucrose and parahydroxybenzoates
ABILIFY oralna otopina sadrži fruktozu, saharozu i parahidroksibenzoate
ABILIFY oral solution contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics.
ABILIFY oralna otopina sadrži djelatnu tvar aripiprazol i pripadju skupini lijekova koji se zovu antipsihotici.
ABILIFY oral solution is used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
ABILIFY oralna otopina se koristi za liječenje odraslih osoba te adolescenata u dobi od 13 godina i starijih koji boluju od stanja čiji su simptomi “povišeno” raspoloženje, pretjerana količina energije, potreba za manjom količinom sna nego obično, vrlo brz govor i ubrzan tijek misli te ponekad teška razdražljivost.
ABILIFY orodispersible tablets are supplied in perforated unit dose blisters packed in cartons containing 14 x 1, 28 x 1, or 49 x 1 orodispersible tablets.
ABILIFY raspadljive tablete se isporučuju u blisterima djeljivima na jedinične doze pakiranima u kutije koje sadrže 14 x 1, 28 x 1 ili 49 x 1 raspadljive tablete.
ABILIFY orodispersible tablets are used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
ABILIFY raspadljive tablete za usta se koriste za liječenje odraslih osoba te adolescenata u dobi od 13 godina i starijih koji boluju od stanja čiji su simptomi “povišeno” raspoloženje, pretjerana količina energije, potreba za manjom količinom sna nego obično, vrlo brz govor i ubrzan tijek misli te ponekad teška razdražljivost.
ABILIFY orodispersible tablets contain aspartame
ABILIFY raspadljive tablete za usta sadrže aspartam
ABILIFY orodispersible tablets contain aspartame, a source of phenylalanine which may be harmful for people with phenylketonuria.
ABILIFY raspadljive tablete za usta sadrže aspartam, izvor fenilalanina koji može naškoditi osobama s fenilketonurijom.
ABILIFY orodispersible tablets contain lactose
ABILIFY raspadljive tablete za usta sadrže laktozu
ABILIFY orodispersible tablets contain lactose.
ABILIFY tablete sadrže laktozu.
ABILIFY orodispersible tablets contain the active substance aripiprazole and belong to a group of medicines called antipsychotics.
ABILIFY raspadljive tablete za usta sadrže djelatnu tvar aripiprazol i pripadaju skupini lijekova koji se zovu antipsihotici.
ABILIFY orodispersible tablets with food, drink and alcohol ABILIFY orodispersible tablets can be taken regardless of meals.
ABILIFY raspadljive tablete za usta s hranom, pićem i alkoholom ABILIFY raspadljive tablete za usta se mogu uzimati neovisno o obrocima.
ABILIFY solution for injection administered intramuscularly as a single-dose to healthy subjects is well absorbed and has an absolute bioavailability of 100 %.
ABILIFY otopina za injekciju primijenjena intramuskularno u obliku jednokratne doze u zdravih ispitanika dobro se apsorbira i ima apsolutnu biološku raspoloživost od 100 %.
ABILIFY solution for injection contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics.
ABILIFY otopina za injekciju sadrži djelatnu tvar aripiprazol i pripada skupini lijekova koji se zovu antipsihotici.
ABILIFY solution for injection is given when treatment with oral formulations is not appropriate.
ABILIFY otopina za injekciju primjenjuje se kad liječenje oralnim pripravcima nije prikladno.
ABILIFY solution for injection is ready to use and intended for short-term use only (see section 5.1).
ABILIFY otopina za injekciju već je pripremljena za primjenu i namijenjena samo za kratkoročnu uporabu (vidjeti dio 5.1).
ABILIFY solution for injection is ready to use.
ABILIFY otopina za injekciju spremna je za primjenu.
ABILIFY solution for injection is used to treat quickly symptoms of agitation and distressing behaviour that may occur in a disease characterised by symptoms such as: hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness.
ABILIFY otopina za injekciju koristi se za brzo uklanjanje simptoma uznemirenosti i poremećenog ponašanja, koji se mogu javiti u bolesti karakteriziranoj simptomima kao što su: situacije u kojima bolesnik čuje, vidi ili osjeća stvari kojih nema, sumnjičavost, pogrešno vjerovanje, nepovezan govor i ponašanje te emocionalna tupost.
Abilify solution for injection was compared with lorazepam (another antipsychotic medicine) and placebo over two hours in one study involving 301 patients experiencing symptoms of agitation.
Otopina za injekcije Abilify uspoređene je lorazepamom (drugim antipsihotikom) i placebom tijekom dva sata u jednom ispitivanju koje je uključivalo 301 bolesnika koji su imali simptome agitacije.
ABILIFY tablets are used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
ABILIFY tablete se koriste za liječenje odraslih osoba te adolescenata u dobi od 13 godina i starijih koji boluju od stanja čiji su simptomi “povišeno” raspoloženje, pretjerana količina energije, potreba za manjom količinom sna nego obično, vrlo brz govor i ubrzan tijek misli te ponekad teška razdražljivost.
ABILIFY tablets contain lactose
ABILIFY tablete sadrže laktozu
ABILIFY tablets contain the active substance aripiprazole and belong to a group of medicines called antipsychotics.
ABILIFY tablete sadrže djelatnu tvar aripiprazol i pripadaju skupini lijekova koji se zovu antipsihotici.
Abilify tablets were also compared with placebo in one study involving 302 patients aged between 13 and 17 years.
Tablete lijeka Abilify također su uspoređene s placebom u jednom ispitivanju koje je uključivalo 302 bolesnika u dobi između 13 i 17 godina.
ABILIFY tablets with food, drink and alcohol ABILIFY tablets can be taken regardless of meals.
ABILIFY tablete s hranom, pićem i alkoholom ABILIFY tablete se mogu uzimati neovisno o obrocima.
Abilify was also compared with placebo in one study involving 296 children and adolescents.
Abilify je također uspoređen s placebom u jednom ispitivanju koje je uključivalo 296 djece i adolescenata.
Abilify was also more effective than placebo at preventing manic episodes returning in previously treated adults for up to 74 weeks, and when it was used as an add-on to existing treatment.
Abilify je također bio djelotvorniji od placeba u sprječavanju povratka maničnih epizoda kod prethodno liječenih odraslih bolesnika do 74 tjedna i kad se koristio kao dodatak postojećoj terapiji.
Abilify was also more effective than placebo over six weeks in the study of adolescents, and the effect of Abilify was maintained for at least six months in patients aged over 15 years.
Abilify je također bio djelotvorniji od placeba tijekom 6 tjedana ispitivanja kod adolescenata, a njegov učinak održan je tijekom najmanje 6 mjeseci kod bolesnika starijih od 15 godina.
Abiraterone is an inhibitor of the hepatic drug-metabolising enzymes CYP2D6 and CYP2C8.
Abirateron je inhibitor jetrenih enzima koji sudjeluju u biotransformaciji lijekova, CYP2D6 i CYP2C8.
Abnormal
neuobičajena
abnormal
poremećaj disanja
Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause.
Abnormalno (nemenstrualno) vaginalno krvarenje bez poznatog/dijagnosticiranog uzroka.
Abnormal arteries, scarring of the arteries, clotting in the arteries, narrowing of the arteries, temporary redness of the face/skin, swelling of the face
Promjene na arterijama, ožiljkavanje arterija, zgrušavanje krvi u arterijama, sužavanje arterija, prolazno crvenilo lica/kože, oticanje lica
Abnormal balance of minerals in the body causing bone problems, bone inflammation, abnormal weakening of the bone leading to bone problems, inflammation of the lining of the joints, rare bone condition
Poremećaj ravnoteže minerala u tijelu koja uzrokuje tegobe s kostima, upala kosti, abnormalno slabljenje kosti koje dovodi do koštanih tegoba, upala ovojnice zglobova, rijetka koštana bolest
Abnormal behaviour, Anxiety,
abnormalno ponašanje, anksioznost,
Abnormal behaviour, confusional state, depressed mood, excitability, feelings of emotional and mental discomfort, feeling of seeing or hearing things that are not really there when you sleep
abnormalno ponašanje, stanje smetenosti, depresivno raspoloženje, uzbuđenost, osjećaj emocionalne i mentalne nelagode, priviđanje stvari koje ne postoje ili umišljanje zvukova koji ne postoje tijekom sna
abnormal behaviour, emotional disorder, fear, nightmare,
neuobičajeno ponašanje, emocionalni poremećaj, strah, noćne more,